Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study

References

• Sandborn WJ. Pouchitis: definition, risk factors, frequency, natural history, classification, and public health perspective. In: McLeod RS, Martin F, Sutherland LR, et al., editors. Trends in Inflammatory Bowel Disease 1996. Lancaster: Kluwer Academic Publishers; 1997. p. 51–63.
   Google Scholar
• de Buck van Overstraeten A, Wolthuis AM, Vermeire S, et al. Long-term functional outcome after ileal pouch anal anastomosis in 191 patients with ulcerative colitis. J Crohn’s Colitis. 2014;8:1261–1266.
   Google Scholar
• Tulchinsky H, Dotan I, Halpern Z, et al. A longitudinal study of quality of life and functional outcome of patients with ulcerative colitis after proctocolectomy with ileal pouch-anal anastomosis. Dis Colon Rectum. 2010;53:866–873.
   PubMed Web of Science ®Google Scholar
• Lepistö A, Luukkonen P, Järvinen HJ. Cumulative failure rate of ileal pouch-anal anastomosis and quality of life after failure. Dis Colon Rectum. 2002;45:1289–1294.
   PubMed Web of Science ®Google Scholar
• Pardi DS, Shen B. Endoscopy in the management of patients after ileal pouch surgery for ulcerative colitis. Endoscopy. 2008;40:529–533.
   PubMed Web of Science ®Google Scholar
• Shen B. Pouchitis: what every gastroenterologist needs to know. Clin Gastroenterol Hepatol. 2013;11:1538–1549.
   PubMed Web of Science ®Google Scholar
• Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39:1193–1196.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment- resistant pouchitis. Aliment Pharmacol Ther. 1999;13:713–718.
   Google Scholar
• Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7:301–305.
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002;16:909–917.
   PubMed Web of Science ®Google Scholar
• Segal JP, Ding NS, Worley G, et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. Aliment Pharmacol Ther. 2017;45:581–592.
   PubMed Web of Science ®Google Scholar
• Pardi DS, D'Haens G, Shen B, et al. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis. 2009;15:1424–1431.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther. 2007;25:1231–1236.
   PubMed Web of Science ®Google Scholar
• Haveran LA, Sehgal R, Poritz LS, et al. Infliximab and/or azathioprine in the treatment of Crohn's disease-like complications after IPAA. Dis Colon Rectum. 2011;54:15–20.
   PubMed Web of Science ®Google Scholar
• Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120–127.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Declerck S, De Hertogh G, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008;14:20–28.
   PubMed Web of Science ®Google Scholar
• Wu H, Shen B. Crohn’s disease of the pouch: diagnosis and management. Expert Rev Gastroenterol Hepatol. 2009;3:155–165.
   PubMedGoogle Scholar
• Herfarth HH, Long MD, Isaacs KL, et al. Use of biologics in pouchitis a systematic review. J Clin Gastroenterol. 2015;49:647–654.
   PubMed Web of Science ®Google Scholar
• Lightner AL, Pemberton JH, Loftus EJ. Crohn's disease of the ileoanal pouch. Inflamm Bowel Dis. 2016;22:1502–1508.
   PubMed Web of Science ®Google Scholar
• Shepherd NA, Jass JR, Duval I, et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol. 1987;40:601–607.
   PubMed Web of Science ®Google Scholar
• Lightner AL, Fletcher JG, Pemberton JH, et al. Crohn's disease of the pouch: a true diagnosis or an oversubscribed diagnosis of exclusion? Dis Colon Rectum. 2017;60:1201–1208.
   PubMed Web of Science ®Google Scholar
• Viazis N, Giakoumis M, Koukouratos T, et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. J Crohns Colitis. 2013;7:e457–e460.
   PubMedGoogle Scholar
• Kelly OB, Rosenberg M, Tyler AD, et al. Infliximab to treat refractory inflammation after pelvic pouch surgery for ulcerative colitis. ECCOJC. 2016;10:410–417.
   Web of Science ®Google Scholar
• Ferrante M, D'Haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis. 2010;16:243–249.
   PubMed Web of Science ®Google Scholar
• Fazio VW, Tekkis PP, Remzi F, et al. Quantification of risk for pouch failure after ileal pouch anal anastomosis surgery. Ann Surg. 2003;238:605–614.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167–182.
   PubMed Web of Science ®Google Scholar
• Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821–826.
   PubMedGoogle Scholar
• Philpott J, Ashburn J, Shen B. Efficacy of vedolizumab in patients with antibiotic and anti-tumor necrosis alpha refractory pouchitis. Inflamm Bowel Dis. 2017;23:E5–E6.
   PubMed Web of Science ®Google Scholar
• Schmid M, Frick J-S, Malek N, et al. Successful treatment of pouchitis with Vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis. Int J Colorectal Dis. 2017;32:597–598.
   PubMed Web of Science ®Google Scholar
• Bethge J, Meffert S, Ellrichmann M, et al. Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. BMJ Open Gastroenterol. 2017;4:e000127.
   PubMed Web of Science ®Google Scholar
• Mir F, Yousef MH, Partyka EK, et al. Successful treatment of chronic refractory pouchitis with vedolizumab. Int J Colorectal Dis. 2017;32:1517–1518.
   PubMed Web of Science ®Google Scholar